Safety and Efficacy Study of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (MK-3475-564/KEYNOTE-564)

NCT03142334 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

994

Enrollment

INDUSTRY

Sponsor class

Conditions

Renal Cell Carcinoma

Interventions

BIOLOGICAL: Pembrolizumab
DRUG: Placebo

Sponsor

Merck Sharp & Dohme LLC